Evaluation of a Person-centred, Nurse-led Model of Care Delivering Hepatitis C Testing and Treatment in Priority Settings: a Mixed-methods Evaluation of the Tasmanian Eliminate Hepatitis C Australia Outreach Project, 2020-2022

Overview

Journal BMC Public Health

Publisher Biomed Central

Specialty Public Health

Date 2023 Nov 21

PMID 37985979

Authors

Joshua Dawe

Megan Hughes

Shannon Christensen

Louisa Walsh

Jacqueline A Richmond

Alisa Pedrana

Anna L Wilkinson

Louise Owen

Joseph S Doyle

Affiliations

Soon will be listed here.

Abstract

Introduction: Australia has experienced sustained reductions in hepatitis C testing and treatment and may miss its 2030 elimination targets. Addressing gaps in community-based hepatitis C prescribing in priority settings that did not have, or did not prioritise, hepatitis C testing and treatment care pathways is critical.

Methods: The Tasmanian Eliminate Hepatitis C Australia Outreach Project delivered a nurse-led outreach model of care servicing hepatitis C priority populations in the community through the Tasmanian Statewide Sexual Health Service, supported by the Eliminating Hepatitis C Australia partnership. Settings included alcohol and other drug services, needle and syringe programs and mental health services. The project provided clients with clinical care across the hepatitis C cascade of care, including testing, treatment, and post-treatment support and hepatitis C education for staff.

Results: Between July 2020 and July 2022, a total of 43 sites were visited by one Clinical Nurse Consultant. There was a total of 695 interactions with clients across 219 days of service delivery by the Clinical Nurse Consultant. A total of 383 clients were tested for hepatitis C (antibody, RNA, or both). A total of 75 clients were diagnosed with hepatitis C RNA, of which 95% (71/75) commenced treatment, 83% (62/75) completed treatment and 52% (39/75) received a negative hepatitis C RNA test at least 12 weeks after treatment completion.

Conclusions: Providing outreach hepatitis C services in community-based services was effective in engaging people living with and at-risk of hepatitis C, in education, testing, and care. Nurse-led, person-centred care was critical to the success of the project. Our evaluation underscores the importance of employing a partnership approach when delivering hepatitis C models of care in community settings, and incorporating workforce education and capacity-building activities when working with non-specialist healthcare professionals.

References

Richmond J, Wallace J . Implementation of hepatitis C cure in Australia: one year on. J Virus Erad. 2018; 4(2):115-117. PMC: 5892669. View

Cashin A, Stasa H, Gullick J, Conway R, Cunich M, Buckley T . Clarifying Clinical Nurse Consultant work in Australia: A phenomenological study. Collegian. 2016; 22(4):405-12. DOI: 10.1016/j.colegn.2014.09.002. View

Richmond J, Gallagher L, McDonald L, OSullivan M, Fitzsimmons C, Pedrana A . Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies. Gastroenterol Nurs. 2020; 43(4):303-309. DOI: 10.1097/SGA.0000000000000458. View

Falade-Nwulia O, Suarez-Cuervo C, Nelson D, Fried M, Segal J, Sulkowski M . Oral Direct-Acting Agent Therapy for Hepatitis C Virus Infection: A Systematic Review. Ann Intern Med. 2017; 166(9):637-648. PMC: 5486987. DOI: 10.7326/M16-2575. View

Grebely J, Bruneau J, Bruggmann P, Harris M, Hickman M, Rhodes T . Elimination of hepatitis C virus infection among PWID: The beginning of a new era of interferon-free DAA therapy. Int J Drug Policy. 2017; 47:26-33. DOI: 10.1016/j.drugpo.2017.08.001. View

Kattakuzhy S, Gross C, Emmanuel B, Teferi G, Jenkins V, Silk R . Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med. 2017; 167(5):311-318. PMC: 5736381. DOI: 10.7326/M17-0118. View

Mason K, Dodd Z, Guyton M, Tookey P, Lettner B, Matelski J . Understanding real-world adherence in the directly acting antiviral era: A prospective evaluation of adherence among people with a history of drug use at a community-based program in Toronto, Canada. Int J Drug Policy. 2017; 47:202-208. DOI: 10.1016/j.drugpo.2017.05.025. View

Kwon J, Dore G, Hajarizadeh B, Alavi M, Valerio H, Grebely J . Australia could miss the WHO hepatitis C virus elimination targets due to declining treatment uptake and ongoing burden of advanced liver disease complications. PLoS One. 2021; 16(9):e0257369. PMC: 8445464. DOI: 10.1371/journal.pone.0257369. View

Ramachandran J, Budd S, Slattery H, Muller K, Mohan T, Cowain T . Hepatitis C virus infection in Australian psychiatric inpatients: A multicenter study of seroprevalence, risk factors and treatment experience. J Viral Hepat. 2018; 26(5):609-612. DOI: 10.1111/jvh.13056. View

10.

Trickey A, Fraser H, Lim A, Peacock A, Colledge S, Walker J . The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study. Lancet Gastroenterol Hepatol. 2019; 4(6):435-444. PMC: 6698583. DOI: 10.1016/S2468-1253(19)30085-8. View

11.

Harney B, Whitton B, Paige E, Brereton R, Weiss R, Membrey D . A multi-site, nurse-coordinated hepatitis C model of care in primary care and community services in Melbourne, Australia. Liver Int. 2021; 42(3):522-531. DOI: 10.1111/liv.15107. View

12.

OSullivan B, Kippen R, Hickson H, Wallace G . Mandatory bulk billing policies may have differential rural effects: an exploration of Australian data. Rural Remote Health. 2022; 22(1):7138. DOI: 10.22605/RRH7138. View

13.

Morris L, Selvey L, Williams O, Gilks C, Kvassy A, Smirnov A . Hepatitis C cascade of care at an integrated community facility for people who inject drugs. J Subst Abuse Treat. 2020; 114:108025. DOI: 10.1016/j.jsat.2020.108025. View

14.

Grebely J, Hajarizadeh B, Lazarus J, Bruneau J, Treloar C . Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all. Int J Drug Policy. 2019; 72:1-10. DOI: 10.1016/j.drugpo.2019.07.016. View

15.

Angeles M, Crosland P, Hensher M . Challenges for Medicare and universal health care in Australia since 2000. Med J Aust. 2023; 218(7):322-329. DOI: 10.5694/mja2.51844. View

16.

Hernandez-Con P, Wilson D, Tang H, Unigwe I, Riaz M, Ourhaan N . Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-Analysis. Am J Prev Med. 2023; 65(6):1153-1162. PMC: 10749988. DOI: 10.1016/j.amepre.2023.06.016. View

17.

Pedrana A, Munari S, Stoove M, Doyle J, Hellard M . The phases of hepatitis C elimination: achieving WHO elimination targets. Lancet Gastroenterol Hepatol. 2020; 6(1):6-8. DOI: 10.1016/S2468-1253(20)30366-6. View

18.

Marshall A, Grebely J, Dore G, Treloar C . Barriers and facilitators to engaging in hepatitis C management and DAA therapy among general practitioners and drug and alcohol specialists-The practitioner experience. Drug Alcohol Depend. 2019; 206:107705. DOI: 10.1016/j.drugalcdep.2019.107705. View

19.

Byrne A, Hegney D, Harvey C, Baldwin A, Willis E, Heard D . Exploring the nurse navigator role: A thematic analysis. J Nurs Manag. 2020; 28(4):814-821. DOI: 10.1111/jonm.12997. View

20.

Lang K, Neil J, Wright J, Dell C, Berenbaum S, El-Aneed A . Qualitative investigation of barriers to accessing care by people who inject drugs in Saskatoon, Canada: perspectives of service providers. Subst Abuse Treat Prev Policy. 2013; 8:35. PMC: 3850796. DOI: 10.1186/1747-597X-8-35. View